Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 23;9(10):e110437.
doi: 10.1371/journal.pone.0110437. eCollection 2014.

Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort

Affiliations

Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort

Anne Sofie Laulund et al. PLoS One. .

Abstract

Introduction and aim: The association between thyroid dysfunction and mortality is controversial. Moreover, the impact of duration of thyroid dysfunction is unclarified. Our aim was to investigate the correlation between biochemically assessed thyroid function as well as dysfunction duration and mortality.

Methods: Register-based follow-up study of 239,768 individuals with a serum TSH measurement from hospitals and/or general practice in Funen, Denmark. Measurements were performed at a single laboratory from January 1st 1995 to January 1st 2011. Cox regression was used for mortality analyses and Charlson Comorbidity Index (CCI) was used as comorbidity score.

Results: Hazard ratios (HR) with 95% confidence intervals (CI) for mortality with decreased (<0.3 mIU/L) or elevated (>4.0 mIU/L) levels of TSH were 2.22; 2.14-2.30; P<0.0001 and 1.28; 1.22-1.35; P<0.0001, respectively. Adjusting for age, gender, CCI and diagnostic setting attenuated the risk estimates (HR 1.23; 95% CI: 1.19-1.28; P<0.0001, mean follow-up time 7.7 years, and HR 1.07; 95% CI: 1.02-1.13; P = 0.004, mean follow-up time 7.2 years) for decreased and elevated values of TSH, respectively. Mortality risk increased by a factor 1.09; 95% CI: 1.08-1.10; P<0.0001 or by a factor 1.03; 95% CI: 1.02-1.04; P<0.0001 for each six months a patient suffered from decreased or elevated TSH, respectively. Subdividing according to degree of thyroid dysfunction, overt hyperthyroidism (HRovert 1.12; 95% CI: 1.06-1.19; P<0.0001), subclinical hyperthyroidism (HRsubclinical 1.09; 95% CI: 1.02-1.17; P = 0.02) and overt hypothyroidism (HRovert 1.57; 95% CI: 1.34-1.83; P<0.0001), but not subclinical hypothyroidism (HRsubclinical 1.03; 95% CI: 0.97-1.09; P = 0.4) were associated with increased mortality.

Conclusions and relevance: In a large-scale, population-based cohort with long-term follow-up (median 7.4 years), overt and subclinical hyperthyroidism and overt but not subclinical hypothyroidism were associated with increased mortality. Excess mortality with increasing duration of decreased or elevated serum TSH suggests the importance of timely intervention in individuals with thyroid dysfunction.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following interests. Bo Abrahamsen has the following interests: Grants from or conducted trials for Novartis, Nycomed/Takeda and Amgen; advisory board member Nycomed/Takeda, Merck and Amgen; and speakers fees from Nycomed/Takeda, Amgen, Merck, Eli Lilly. Laszlo Hegedüs is a consultant for and is supported by an unrestricted grant from the Novo Nordisk Foundation. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Figures

Figure 1
Figure 1. Cox proportional hazards models.
Decreased TSH (<0.3 mlU/L) (panel A) and elevated TSH (>4 mlU/L) (panel B) as predictors of mortality. The figure illustrates the crude hazard ratios and the adjusted hazard ratios from the Cox regression analysis with stepwise addition of the covariates. Population N = 239768. ** P<0.0001.

References

    1. Brown-Borg HM (2007) Hormonal regulation of longevity in mammals. Ageing Res Rev 6: 28–45. - PMC - PubMed
    1. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD (2007) Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 49: 71–81. - PubMed
    1. Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP (2006) Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 91: 2159–2164. - PubMed
    1. Brandt F, Thvilum M, Almind D, Christensen K, Green A, et al. (2013) Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One 8: e66711. - PMC - PubMed
    1. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, et al. (2005) Thyroid disease and increased cardiovascular risk. Thyroid 15: 718–724. - PubMed

Publication types